King's Research Portal

DOI:

[10.1111/odi.12410](https://doi.org/10.1111/odi.12410)

Document Version

Peer reviewed version

[Link to publication record in King's Research Portal](#)

Citation for published version (APA):

Moyes, D. L., Islam, A., Kohli, A., & Naglik, J. R. (2016). Oral epithelial cells and their interactions with HIV-1. *Oral Diseases*, 22(S1). <https://doi.org/10.1111/odi.12410>

Citing this paper

Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination, volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are again advised to check the publisher's website for any subsequent corrections.

General rights

Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the Research Portal

Take down policy

If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.

1 **Oral epithelial cells and their interactions with HIV-1**

2 **HIV-1 and the oral epithelium**

3

4 David L. Moyes^{1*}, Ayesha Islam¹, Arinder Kohli², Julian R. Naglik¹

5 ¹ Mucosal & Salivary Biology Division, King's College London Dental Institute, King's College London,
6 London, SE1 1UL, UK

7 ² Arinder's address

8 *Corresponding author, e-mail: david.moyes@kcl.ac.uk

9 Key Words: HIV, AIDS, epithelial cells, oral epithelium, infectious disease, mucosal immunity

10

Abstract

As the AIDS pandemic has continued, our understanding of the events that occur during the entry and infection of conventional, susceptible cells has increased dramatically, leading to the development of control therapies for HIV infected individuals. However, an ongoing hole in our understanding is how HIV crosses the mucosal barriers to gain access to permissive cells, despite how important this information would be in developing successful vaccines and other preventative measures such as topical anti-HIV microbicides. In particular, our knowledge of the role that epithelial cells of the mucosal surfaces play in infection – both during early phases and throughout the life of an infected individual, is currently hazy at best. However, several studies in recent years suggest that HIV can bind to and traverse these mucosal epithelial cells, providing a reservoir of infection that can subsequently infect underlying permissive cells. Despite this interaction with epithelial cells, evidence suggests HIV-1 does not productively infect these cells, although they are capable of transferring surface-bound and transcytosed virus to other, permissive cells. Further, there appear to be key differences between adult and infant epithelial cells in the degree to which HIV can transcytose and infect the epithelium. Thus, it is clear that, whilst not primary targets for infection and virus replication, epithelial cells play an important role in the infection cycle and improving our understanding of their interactions with HIV could potentially provide key insights necessary to develop effective preventative therapies.

29 **Introduction**

30 Despite a reduction in the number of articles about the HIV epidemic in the Western press over the
31 last two decades, HIV infection is a major ongoing issue in global health. Recent epidemiology
32 figures indicate that at the end of 2014 there were approximately 37 million people living with HIV.
33 During 2014, approximately 2 million fresh cases of infection were reported, whilst around 1.2
34 million people died of HIV/AIDS related illness (UNAIDS, 2015). This, however, could be just the tip of
35 the iceberg. Estimates suggest that only about 50% of cases are reported, implying that the true
36 figures for infection are much higher. Although the introduction of HAART therapy has been a bright
37 spot in the landscape of the HIV Pandemic (along with other measures, the era of HAART therapy
38 has seen a 42% drop in annual mortality in 2014 since its peak in 2004), we are currently still no
39 closer to developing effective therapies such as vaccines and topical anti-HIV microbicides that could
40 be used to prevent infection in the first place. A key step in the fight to develop these therapeutics is
41 improving our currently poor understanding of HIV infection at mucosal surfaces.

42 The primary infection route for HIV-1 is across mucosal surfaces such as the gastrointestinal and
43 genital tracts (Hladik & McElrath, 2008), with exposure occurring during events such as sexual
44 activity and breast-feeding. Currently, the majority of new infections occur as a result of
45 heterosexual transmission in adults, with HIV-1 having been isolated from both seminal fluid and
46 cervicovaginal secretions (Coombs et al., 1998, Dulioust et al., 1998, Goulston et al., 1998). In
47 infants, however, infection by HIV-1 typically occurs as a result of breast-feeding, with the oral and
48 oropharyngeal tissues representing the initial exposure sites. Effective transmission across genital
49 mucosal surfaces (in particular, the vagina, ecto-and endocervix and uterus) is assisted by the
50 presence of HIV-1 target cells within these surfaces, such as dendritic cells, macrophages and
51 lymphocytes (Yeaman et al., 1998, Ballweber et al., 2011, Shen et al., 2011, Kaldensjo et al., 2011,
52 Hladik et al., 2007, Miller & Shattock, 2003, Bhoopat et al., 2001, Hu et al., 2004, Maher et al., 2005).
53 Indeed, it has been established that dendritic cells can sample mucosal surfaces such as the gut

directly, without needing antigens to be transported through the epithelial layer (Niess et al., 2005). However, a subset of dendritic cells, the Langerhans cells, has been shown to have an anti-HIV function, mediated by the Langerin surface receptor (de Witte et al., 2007), and these cells are known to be present in oral mucosa (Hussain & Lehner, 1995). The key role of both dendritic and Langerhans cells in HIV infection is extensively reviewed elsewhere (van den Berg & Geijtenbeek, 2013). Despite the apparent ease with which HIV crosses the genital and rectal mucosa, transmission across the oral mucosa is thought to be rare (Milman & Sharma, 1994, Janoff & Smith, 2001, Wilkinson & Cunningham, 2006, Cohen et al., 2000, Rothenberg et al., 1998, Jotwani et al., 2004), with several mechanisms (such as neutralizing antibodies, innate anti-HIV salivary factors, presence of Langerhans cells and the epithelium) proposed to explain this phenomenon (Challacombe & Naglik, 2006, Herzberg et al., 2006, Kazmi et al., 2006, Malamud & Wahl, 2010, Weinberg et al., 2011). Despite this, oral transmission can occur. For example, SIV transmission across non-traumatised oral epithelia, resulting in dissemination and systemic infection in primates has been reported in several studies (Baba et al., 1996, Herz et al., 2002, Joag et al., 1997, Milush et al., 2004). As a result, the epithelium may represent either a physical barrier against direct infection or a potential reservoir to aid infection. The importance of determining which of these is prevalent is of particular importance, given the potential for viral transference in nursing infants or during oro-genital contact in adults.

Initial contact with oral mucosa

The initial contact between the host and HIV-1 in the oral cavity occurs between virus and the oral and oropharyngeal mucosal tissues (Herzberg et al., 2006). However, given the variety of cell types, along with the preponderance of epithelial cells in these tissues, neither the primary infected cell type, nor the initial site of infection has as yet been identified. It has become evident, however, that upon exposure of these sites to the virus, an anti-HIV response is generated. For example, after unprotected oro-genital contact with an HIV⁺ partner, uninfected men have been shown to mount a

salivary IgA1 response that neutralises the HIV-1 virions (Hasselrot et al., 2009), thus demonstrating that far from remaining ignorant of the presence of the virion, these surfaces are capable of recognising and responding to HIV-1. What is unclear is where the response is initiated. Are these responses a result of viral interaction with and infection of resident infectable immune cells such as langerhans dendritic cells or macrophages or, more controversially, are they instigated through recognition of viral particles by the epithelial cells that make up the majority of these surfaces? On the face of it, this seems like an easy answer - epithelial cells are not known for their expression of the canonical receptors for HIV - namely CD4, CCR5 and CXCR4, so they should not be infected or interact directly with the virus. Further, extensive research over the years has identified CD4⁺ T cells and macrophages, along with dendritic cells, as being the key target cells of the HIV virus. However, over the last decade, there has been a small but persistent number of studies from different groups suggesting that HIV can interact, associate with or even infect epithelial cells (Vacharaksa et al., 2008, Kohli et al., 2014, Rodriguez-Inigo et al., 2005, Liu et al., 2003, Moore et al., 2002, Moore et al., 2003). These studies suggests that oral epithelial cells themselves may play a key role in the initial contact events in the oral cavity, possibly being the initial point of contact. However, whether the epithelial cells that make up the oral mucosa can serve as a reservoir for HIV-1 virions during initial or subsequent infection events, or even if they can function as a seat of infection remains uncertain (Richman et al., 2009). The importance of the oral mucosa in HIV infection, however, cannot be ignored. Whilst anti-HIV immune responses are generated, augmentation of these responses with topical anti-HIV agents (Li et al., 2009) strongly suggests that infection and evasion of immune responses at the oral mucosae represents a potential route of infection.

Epithelial cells - infected or bound?

Inherent to the question of whether oral (or other) epithelial cells can be infected by HIV-1, is whether they possess the correct, canonical HIV receptors – CD4 and CXCR4 or CCR5. The target cells of an HIV-1 infection (T cells, dendritic cells and macrophages) all express CD4 and either or both of

the chemokine co-receptors, CXCR4 or CCR5. The events during infection of these cells have been the source of much research and has now been fairly well characterised (Pierson & Doms, 2003). Initial contact between the viral envelope protein gp120 and host cell CD4 leads to a conformational change in gp120 followed by further interaction with one or other of the fusion co-receptors, CCR5 or CXCR4. This leads to gp41-mediated fusion of the viral membrane with the host cell membrane, allowing entry into the cell. Once inside the cell, the HIV-1 RNA genome is reverse transcribed into DNA and integrated into the host cell genome. Thus, it would appear that a central requirement in the infection of a cell is the expression of CD4 and either or both of CCR5 and CXCR4. Studies by several groups have clearly demonstrated that, unlike classical HIV-infectable cells (T cells etc), epithelial cells do not express CD4 (Liu et al., 2003, Kumar et al., 2006, Quinones-Mateu et al., 2003, Vacharaksa et al., 2008, Kohli et al., 2014, Walsh et al., 1990), whilst levels of CXCR4 and CCR5 are either very low or undetectable (Kohli et al., 2014, Liu et al., 2013, Vacharaksa et al., 2008, Cutler & Jotwani, 2006, Giacaman et al., 2008, Berlier et al., 2005, Bobardt et al., 2007, Dezzutti et al., 2001).

Given this apparent lack of HIV-1 binding cellular receptors, the question is how do HIV-1 virions bind to epithelial cells? The answer to this question is via the use of alternative HIV-associative receptors. Over the course of the history of HIV-1 research, several different groups have demonstrated that in addition to the 'canonical' receptors CD4 and CCR5/CXCR4, HIV-1 can also bind to a selection of other cell surface receptors or moieties, utilising substitute mechanisms of binding and cellular entry (**Table 1**). For example, the viral envelope protein gp160 (gp120 and gp41) binds to, among others, DC-SIGN (dendritic cell-specific intercellular adhesion molecule-3-grabbing non-integrin) (Geijtenbeek et al., 2000, van Kooyk & Geijtenbeek, 2003), GalCer (the glycosphingolipid galactosylceramide) (Alfsen & Bomsel, 2002, Delezay et al., 1997, Harouse et al., 1991) and heparan sulphate glycans (HSPGs) including the syndecan family receptors (Bobardt et al., 2003, Wu et al., 2003). Each of these receptors has been shown to play a role in either simply binding the virus and 'passing it on' to target cells (*trans*-infection) or, in some cases, enhance direct infection of the binding cell (*cis*-infection) by an active process as well (e.g. D-SIGN). Most notable of these is the C-

type lectin DC-SIGN. Work investigating the interactions of this lectin with HIV-1 gp120 have indicated that as well as enhancing infection by increasing the concentration of virus on the cellular surface, it also increases the affinity of gp120 for CD4 (Hijazi et al., 2011). Both GalCer (Magerus-Chatinet et al., 2007) and HPSGs (Jiang et al., 2015) have also been shown to play a role in *trans*-infection.

These 'non-canonical' receptor moieties are expressed on a wider range of cell types than CD4 and the chemokine co-receptors. Both GalCer and HSPGs in particular have been shown to be abundantly expressed in oral epithelial cells, although DC-SIGN is not (Kohli et al., 2014). This expression on the epithelial cell component has been proposed as a mechanism promoting the binding and transfer of HIV-1 virions across both the oral and vaginal epithelial layers thus improving/aiding initial infection events (Bobardt et al., 2007, Dezzutti et al., 2001, Weinberg et al., 2011, Wu et al., 2003, Yeaman et al., 1998). Given that these interaction processes between non-canonical receptors and HIV-1 are regarded as being co-receptor independent (CXCR4/CCR5), it is, therefore, somewhat of a surprise that the R5-tropic HIV-1 viruses (those that utilise CCR5 as a co-receptor) appear to be preferentially transmitted across mucosal surfaces (Margolis & Shattock, 2006).

Although there is currently no evidence to indicate that any of these non-canonical receptors can directly initiate *cis*-infection of an epithelial cell in a CD4+/CCR5/CXCR4 independent fashion, there have been studies published that suggest that HIV-1 is capable of infecting and integrating into oral (Vacharaksa et al., 2008) and genitourinary tract (Hladik et al., 2007) epithelial cells, although in both cases, this infection was non-productive - *i.e.* does not result in the production of viral transcripts or progeny virions. However, in a more recent study, we demonstrated using a variety of techniques that whilst both X4- and R5-tropic HIV-1 could bind to oral and vaginal epithelial cells, they were unable to infect - productively or unproductively (Kohli et al., 2014). When analysed, virus treated cells showed not only showed no infective virion production when the virions were pre-treated with

DNase to remove any nucleic acid contamination. They also demonstrated no proviral integration, spliced viral mRNA or *de novo* synthesis of viral proteins. The absence of all these indicators of viral infection and production indicate that although oral and vaginal epithelial cells have a variety of non-canonical HIV receptors on their surface, they appear to be non-permissive to viral infection by the HIV-1 virus. It is notable that this non-permissivity to infection by HIV-1 is not down to an inherent inability of HIV-1 to replicate in epithelial cells. We found that if a VSV-G pseudotyped *gfp* containing HIV-1 virus (guaranteeing entry via the endocytic pathway) was used to infect epithelial cells, then normal proviral integration could occur, with infected cells expressing GFP at similar levels to a permissive cell line. Together with the existence of reporter 'permissive' cell lines that express CD4, CCR5 and/or CXCR4, such as the TZM-bl line, that are based on epithelial cells, this data suggests that if the HIV-1 virion can gain entry to oral epithelial cells in a receptor-independent or other non-conventional mechanisms (such as endocytosis), then this could potentially lead to the production of infectious virions. Thus, it is possible that when conditions arise *in vivo* that facilitate bypassing receptor-mediated entry (e.g. during inflammation events such as gingivitis when cells are damaged, or by 'piggy backing' on another microbe), epithelial cells in the epithelium could support productive HIV-1 infections, potentially by harbouring infectious HIV-1 that is then *trans*-infected to incoming permissive immune cells (Giavedoni et al., 2013).

Despite the inability of HIV-1 to successfully infect epithelial cells, however, we like several other studies found that HIV virions can be bound by epithelial cells, as indicated by the presence of both gp120 and p24 on infected epithelial cells (determined by flow cytometry and immunoblotting), and the presence of HIV-1 RNA genome (determined by PCR on RNA isolated from infected cells). Interestingly, there are difference in the amount of virus bound by epithelial cells from different locations, with the oropharyngeal FaDu epithelial cell line binding more than either a buccal or vulvovaginal cell line. The binding (likely through non-canonical receptors) also proved to be trypsin-sensitive, particularly for the R5 tropic virus (Kohli et al., 2014), suggesting a degree of protein involvement. Thus, from our study and others, it appears that HIV-1 does indeed bind to epithelial

cells, although there are differences between cells from different locations. These differences likely reflect differences in the expression of the different non-canonical receptors on their surfaces, and may well change with the age and infection status of an individual, as well as with any drug regimen the individual is on.

Epithelial cell transfer of HIV-1

Given that HIV-1 can demonstrably bind to epithelial cells, albeit without any accompanying *cis*-infection, the question arises whether epithelial cells can act as a reservoir in some way for the virus. The hypothesis would be that surface-bound HIV can be transferred from epithelial cells to other, susceptible cells, such as dendritic cells, macrophages and T cells integrated in or underlying the epithelial layer. Although there is a study which was unable to demonstrate successful transfer of infectious HIV-1 to permissive PBMCs (peripheral blood mononuclear cells) (Berlier et al., 2005), there are several studies that have produced evidence to support the hypothesis (Yeaman et al., 1998, Ballweber et al., 2011, Shen et al., 2011, Hladik et al., 2007, Khanna et al., 2002, Miller & Shattock, 2003, Dezzutti et al., 2001, Spira et al., 1996, Hu et al., 2000). With this in mind, we tested whether epithelial cell-bound HIV could be successfully transferred to a reporter cell line using an overlay system, and demonstrated that both R5 and X4-tropic virus were capable of retaining infectivity and being transferred to susceptible cells after being bound by epithelial cells (Kohli et al., 2014). Others have also shown HIV binding activity for oral cells (Liu et al., 2003, Vacharaksa et al., 2008, Wu et al., 2003, Mondor et al., 1998, Roderiquez et al., 1995), which supports the hypothesis that oral epithelial cells can bind HIV-1 and transfer it to other cells, acting as a 'sump' or reservoir for the virus - whether it has been produced locally or has come from an external source. What is not clear at this time is the receptors responsible for this binding. It is clear from studying the effects of trypsin treatment on the levels of binding that there is some protein interaction involved. Likewise, studies examining the effects of heparin or heparin sulfate (blocking binding through HSPGs) indicate that these treatments can also reduce viral attachment (Bobardt et al., 2003, Wu et

al., 2003, Mondor et al., 1998, Roderiquez et al., 1995). However, there is no current definitive proof for one specific moiety on either side being key. The likelihood is that there are a range of receptor/ligand interactions on both virion and host epithelial cell that all play differing roles, depending on the site, environment and other factors.

Binding and transferring the virus is only one part of the story, however. Most of the HIV-1 susceptible cells in mucosal surfaces are present at lower levels than the top of the epithelium. Thus, to be a truly effective source of viral transmission, it is necessary for the virus to be transported through the epithelial layer whilst retaining infectivity. Using transwell cultures, we demonstrated the transcytosis of infectious virus through an oral or vaginal epithelial cell layer, with successful infection of susceptible cells on the basal side of the monolayer (Kohli et al., 2014). Other studies have also shown transcytosis through vaginal epithelial layers (Kinlock et al., 2014, Ferreira et al., 2015). Interestingly, these studies indicate that this is an endocytic pathway dependent mechanism (Kinlock et al., 2014), and that the female hormone medroxyprogesterone acetate boosts the transit and subsequent infection (Ferreira et al., 2015). A further study has also implicated anti-HIV-1 antibody-neonatal Fc receptor interactions as also playing an enhancing role in the transcytosis of HIV across an epithelial cell surface (Gupta et al., 2013). This strongly suggests that host factors are critical in regulating the transport of HIV virions across epithelial surfaces deeper into the layer and thus subsequent infection of susceptible cells in these tissues. More, HIV-1 is able to hijack host mechanisms to boost this event. Investigations using *in vivo* models suggest that HIV can indeed successfully pass through the epithelial layer to permissive cells, although much of this work has been carried out looking at vaginal/genitourinary mucosa (Ferreira et al., 2015; Spira, 1996 #1936, Hu et al., 2000, Baba et al., 1996, Herz et al., 2002, Joag et al., 1997, Milush et al., 2004).

The data obtained from all these studies lead us to develop the hypothesis that the epithelial cells at oral and other mucosal surfaces not only bind cell free HIV, but that they also transport infectious virions deeper into the mucosal layers where they can infect susceptible cells.

Further considerations

It is clearly apparent that different conditions/environments at mucosal surfaces can materially affect the movement and maintenance of HIV-1 virions within the mucosae. What we have seen here is that there are differences in the transmission rates of epithelial surfaces depending on the status of the epithelial cells or production of host factors. This then leads us to wonder whether the transmission of virus through the oral epithelium varies with the age of the host. This is of particular interest, given the rate of transmission from mother to child. This mother to child transmission (MTCT) can occur during pregnancy, labour and delivery or through breast feeding after birth (Politch et al., 2014). MTCT during pregnancy and labour/delivery occurs in 15-25% of cases unless specific interventions are made, but a further 5-20% of infants will be infected as a result of post-natal breast feeding (Politch et al., 2014, Roskoski, 2014). Given the low incidence of transmission traditionally associated with oral sex (Smith et al., 2005), this suggests that there may be something different about neonatal/foetal oral epithelium that allows a significant number of infectious events due to transmission across the oral mucosa. Two recent studies from Tugizov et al suggest that this might be the case (Tugizov et al., 2011, Tugizov et al., 2012). In these studies, the authors determined that there was a significant number in the amount of HIV virions that successfully traversed the oral epithelium and infected the underlying susceptible cells in fetal/neonatal oral epithelium. In contrast, transmission through adult epithelium was reduced. Further, HIV-1 virions transcytosed through adult oral epithelium showed reduced infectivity, whereas those transcytosed through foetal/neonatal epithelium (Tugizov et al., 2011). The likelihood is that this reduction is due to an increase in the secretion of anti-HIV factors such as β -defensins 2 and 3, as well as secretory

leukocyte protease inhibitor (Tugizov et al., 2011). Thus the age of the host is also a key factor in the transmission of HIV virions across the epithelial surfaces.

Summary

As we have seen throughout this review, the oral epithelium and the epithelial cells that comprise the majority of these surfaces are not simply a passive barrier during HIV-1 infections. In contrast, they have a significant role to play in infection events as well as potentially acting as reservoirs for infection. We propose that under normal conditions HIV-1 will bind to adult epithelial cells in the oral epithelium, but that this binding will not result in productive infection. However, post-capture, some of these virus particles may be retained and translocated through the epithelial layer to underlying target cells which can then be productively infected, although a large percentage of these virions may be killed or inactivated by host factors. In neonates, however, these host factors play a far more minor role, meaning that transmission across oral epithelium via epithelial cells and subsequent infection of susceptible cells is a far more common event. Thus, further targeting epithelial cells and the epithelium in general, particularly in neonates and infants represents a highly viable preventative therapy to halt the spread of HIV infection.

Acknowledgments

This work was supported by NIDCR DE017514 (to J.N.) Medical Research Council (MR-J008303-1) (to J.R.N. and D.L.M.) and Biotechnology and Biological Sciences Research Council (BB-J016411-1). (to J.R.N. and D.L.M.)

Table 1: List of non-canonical HIV receptors.

Receptor	Role	Reference
DC-SIGN	Binds HIV gp120; increases affinity of gp120 for CD4; increases infectivity	(Hijazi et al., 2011)
Galctosyl Ceramide	Binds HIV gp120; allows HIV to bind cells in a CD4 independent fashion	(Magerus-Chatinet et al.,

		2007)
Heparan sulfate glycans	Binds HIV gp120; allows HIV to bind cells in a CD4 independent fashion	(Jiang et al., 2015)

References

- Alfsen A and Bomsel M (2002). HIV-1 gp41 envelope residues 650-685 exposed on native virus act as a lectin to bind epithelial cell galactosyl ceramide. *The Journal of biological chemistry* 277: 25649-59.
- Baba TW, Trichel AM, An L, Liska V, Martin LN, Murphey-Corb M and Ruprecht RM (1996). Infection and AIDS in adult macaques after nontraumatic oral exposure to cell-free SIV. *Science* 272: 1486-9.
- Ballweber L, Robinson B, Kreger A, Fialkow M, Lentz G, McElrath MJ and Hladik F (2011). Vaginal langerhans cells nonproductively transporting HIV-1 mediate infection of T cells. *Journal of virology* 85: 13443-7.
- Berlier W, Bourlet T, Lawrence P, Hamzeh H, Lambert C, Genin C, Verrier B, Dieu-Nosjean MC, Pozzetto B and Delezay O (2005). Selective sequestration of X4 isolates by human genital epithelial cells: Implication for virus tropism selection process during sexual transmission of HIV. *J Med Virol* 77: 465-74.
- Bhoopat L, Eiangleng L, Rugpao S, Frankel SS, Weissman D, Lekawanvijit S, Petchjom S, Thorner P and Bhoopat T (2001). In vivo identification of Langerhans and related dendritic cells infected with HIV-1 subtype E in vaginal mucosa of asymptomatic patients. *Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc* 14: 1263-9.
- Bobardt MD, Chatterji U, Selvarajah S, Van der Schueren B, David G, Kahn B and Gallay PA (2007). Cell-free human immunodeficiency virus type 1 transcytosis through primary genital epithelial cells. *Journal of virology* 81: 395-405.
- Bobardt MD, Saphire AC, Hung HC, Yu X, Van der Schueren B, Zhang Z, David G and Gallay PA (2003). Syndecan captures, protects, and transmits HIV to T lymphocytes. *Immunity* 18: 27-39.
- Challacombe SJ and Naglik JR (2006). The effects of HIV infection on oral mucosal immunity. *Advances in dental research* 19: 29-35.
- Cohen MS, Shugars DC and Fiscus SA (2000). Limits on oral transmission of HIV-1. *Lancet* 356: 272.
- Coombs RW, Speck CE, Hughes JP, Lee W, Sampoleo R, Ross SO, Dragavon J, Peterson G, Hooton TM, Collier AC, Corey L, Koutsky L and Krieger JN (1998). Association between culturable human immunodeficiency virus type 1 (HIV-1) in semen and HIV-1 RNA levels in semen and blood: evidence for compartmentalization of HIV-1 between semen and blood. *The Journal of infectious diseases* 177: 320-30.
- Cutler CW and Jotwani R (2006). Oral mucosal expression of HIV-1 receptors, co-receptors, and alpha-defensins: tableau of resistance or susceptibility to HIV infection? *Advances in dental research* 19: 49-51.

306 de Witte L, Nabatov A, Pion M, Fluitsma D, de Jong MA, de Gruijl T, Piguet V, van Kooyk Y and
307 Geijtenbeek TB (2007). Langerin is a natural barrier to HIV-1 transmission by Langerhans cells. *Nat*
308 *Med* 13: 367-71.

309 Delezay O, Koch N, Yahi N, Hammache D, Tourres C, Tamalet C and Fantini J (1997). Co-expression of
310 CXCR4/fusin and galactosylceramide in the human intestinal epithelial cell line HT-29. *AIDS* 11: 1311-
311 8.

312 Dezzutti CS, Guenther PC, Cummins JE, Jr., Cabrera T, Marshall JH, Dillberger A and Lal RB (2001).
313 Cervical and prostate primary epithelial cells are not productively infected but sequester human
314 immunodeficiency virus type 1. *The Journal of infectious diseases* 183: 1204-13.

315 Dulioust E, Tachet A, De Almeida M, Finkielstejn L, Rivalland S, Salmon D, Sicard D, Rouzioux C and
316 Jouannet P (1998). Detection of HIV-1 in seminal plasma and seminal cells of HIV-1 seropositive men.
317 *J Reprod Immunol* 41: 27-40.

318 Ferreira VH, Dizzell S, Nazli A, Kafka JK, Mueller K, Nguyen PV, Tremblay MJ, Cochrane A and Kaushic
319 C (2015). Medroxyprogesterone Acetate Regulates HIV-1 Uptake and Transcytosis but Not
320 Replication in Primary Genital Epithelial Cells, Resulting in Enhanced T-Cell Infection. *The Journal of*
321 *infectious diseases* 211: 1745-56.

322 Geijtenbeek TB, Kwon DS, Torensma R, van Vliet SJ, van Duijnhoven GC, Middel J, Cornelissen IL,
323 Nottet HS, KewalRamani VN, Littman DR, Figdor CG and van Kooyk Y (2000). DC-SIGN, a dendritic
324 cell-specific HIV-1-binding protein that enhances trans-infection of T cells. *Cell* 100: 587-97.

325 Giacaman RA, Asrani AC, Gebhard KH, Dietrich EA, Vacharaksa A, Ross KF and Herzberg MC (2008).
326 Porphyromonas gingivalis induces CCR5-dependent transfer of infectious HIV-1 from oral
327 keratinocytes to permissive cells. *Retrovirology* 5: 29.

328 Giavedoni LD, Chen HL, Hodara VL, Chu L, Parodi LM, Smith LM, Sexton V, Cappelli D and Sodora DL
329 (2013). Impact of mucosal inflammation on oral simian immunodeficiency virus transmission. *Journal*
330 *of virology* 87: 1750-8.

331 Goulston C, McFarland W and Katzenstein D (1998). Human immunodeficiency virus type 1 RNA
332 shedding in the female genital tract. *The Journal of infectious diseases* 177: 1100-3.

333 Gupta S, Gach JS, Becerra JC, Phan TB, Pudney J, Moldoveanu Z, Joseph SB, Landucci G, Supnet MJ,
334 Ping LH, Corti D, Moldt B, Hel Z, Lanzavecchia A, Ruprecht RM, Burton DR, Mestecky J, Anderson DJ
335 and Forthal DN (2013). The Neonatal Fc receptor (FcRn) enhances human immunodeficiency virus
336 type 1 (HIV-1) transcytosis across epithelial cells. *PLoS pathogens* 9: e1003776.

337 Harouse JM, Bhat S, Spitalnik SL, Laughlin M, Stefano K, Silberberg DH and Gonzalez-Scarano F
338 (1991). Inhibition of entry of HIV-1 in neural cell lines by antibodies against galactosyl ceramide.
339 *Science* 253: 320-3.

340 Hasselrot K, Saberg P, Hirbod T, Soderlund J, Ehnlund M, Bratt G, Sandstrom E and Broliden K (2009).
341 Oral HIV-exposure elicits mucosal HIV-neutralizing antibodies in uninfected men who have sex with
342 men. *AIDS* 23: 329-33.

343 Herz AM, Robertson MN, Lynch JB, Schmidt A, Rabin M, Sherbert C, Agy MB, Anderson D, Hu SL,
 344 Greenberg PD and Morton WR (2002). Viral dynamics of early HIV infection in neonatal macaques
 345 after oral exposure to HIV-2287: an animal model with implications for maternal-neonatal HIV
 346 transmission. *Journal of medical primatology* 31: 29-39.

347 Herzberg MC, Weinberg A and Wahl SM (2006). (C3) The oral epithelial cell and first encounters with
 348 HIV-1. *Advances in dental research* 19: 158-66.

349 Hijazi K, Wang Y, Scala C, Jeffs S, Longstaff C, Stieh D, Haggarty B, Vanham G, Schols D, Balzarini J,
 350 Jones IM, Hoxie J, Shattock R and Kelly CG (2011). DC-SIGN increases the affinity of HIV-1 envelope
 351 glycoprotein interaction with CD4. *PloS one* 6: e28307.

352 Hladik F and McElrath MJ (2008). Setting the stage: host invasion by HIV. *Nat Rev Immunol* 8: 447-57.

353 Hladik F, Sakchalathorn P, Ballweber L, Lentz G, Fialkow M, Eschenbach D and McElrath MJ (2007).
 354 Initial events in establishing vaginal entry and infection by human immunodeficiency virus type-1.
 355 *Immunity* 26: 257-70.

356 Hu J, Gardner MB and Miller CJ (2000). Simian immunodeficiency virus rapidly penetrates the
 357 cervicovaginal mucosa after intravaginal inoculation and infects intraepithelial dendritic cells. *Journal*
 358 *of virology* 74: 6087-95.

359 Hu Q, Frank I, Williams V, Santos JJ, Watts P, Griffin GE, Moore JP, Pope M and Shattock RJ (2004).
 360 Blockade of attachment and fusion receptors inhibits HIV-1 infection of human cervical tissue. *J Exp*
 361 *Med* 199: 1065-75.

362 Hussain LA and Lehner T (1995). Comparative investigation of Langerhans' cells and potential
 363 receptors for HIV in oral, genitourinary and rectal epithelia. *Immunology* 85: 475-84.

364 Janoff EN and Smith PD (2001). Emerging concepts in gastrointestinal aspects of HIV-1 pathogenesis
 365 and management. *Gastroenterology* 120: 607-21.

366 Jiang AP, Jiang JF, Guo MG, Jin YM, Li YY and Wang JH (2015). Human Blood-Circulating Basophils
 367 Capture HIV-1 and Mediate Viral trans-Infection of CD4+ T Cells. *Journal of virology* 89: 8050-62.

368 Joag SV, Adany I, Li Z, Foresman L, Pinson DM, Wang C, Stephens EB, Raghavan R and Narayan O
 369 (1997). Animal model of mucosally transmitted human immunodeficiency virus type 1 disease:
 370 intravaginal and oral deposition of simian/human immunodeficiency virus in macaques results in
 371 systemic infection, elimination of CD4+ T cells, and AIDS. *Journal of virology* 71: 4016-23.

372 Jotwani R, Muthukuru M and Cutler CW (2004). Increase in HIV receptors/co-receptors/alpha-
 373 defensins in inflamed human gingiva. *Journal of dental research* 83: 371-7.

374 Kaldensjo T, Petersson P, Tolf A, Morgan G, Broliden K and Hirbod T (2011). Detection of
 375 intraepithelial and stromal Langerin and CCR5 positive cells in the human endometrium: potential
 376 targets for HIV infection. *PloS one* 6: e21344.

377 Kazmi SH, Naglik JR, Sweet SP, Evans RW, O'Shea S, Banatvala JE and Challacombe SJ (2006).
378 Comparison of human immunodeficiency virus type 1-specific inhibitory activities in saliva and other
379 human mucosal fluids. *Clinical and vaccine immunology* : CVI 13: 1111-8.

380 Khanna KV, Whaley KJ, Zeitlin L, Moench TR, Mehrazar K, Cone RA, Liao Z, Hildreth JE, Hoen TE,
381 Shultz L and Markham RB (2002). Vaginal transmission of cell-associated HIV-1 in the mouse is
382 blocked by a topical, membrane-modifying agent. *J Clin Invest* 109: 205-11.

383 Kinlock BL, Wang Y, Turner TM, Wang C and Liu B (2014). Transcytosis of HIV-1 through vaginal
384 epithelial cells is dependent on trafficking to the endocytic recycling pathway. *PLoS one* 9: e96760.

385 Kohli A, Islam A, Moyes DL, Murciano C, Shen C, Challacombe SJ and Naglik JR (2014). Oral and
386 vaginal epithelial cell lines bind and transfer cell-free infectious HIV-1 to permissive cells but are not
387 productively infected. *PLoS one* 9: e98077.

388 Kumar RB, Maher DM, Herzberg MC and Southern PJ (2006). Expression of HIV receptors, alternate
389 receptors and co-receptors on tonsillar epithelium: implications for HIV binding and primary oral
390 infection. *Virology* 3: 25.

391 Li Q, Estes JD, Schlievert PM, Duan L, Brosnahan AJ, Southern PJ, Reilly CS, Peterson ML, Schultz-
392 Darken N, Brunner KG, Nephew KR, Pambuccian S, Lifson JD, Carlis JV and Haase AT (2009). Glycerol
393 monolaurate prevents mucosal SIV transmission. *Nature* 458: 1034-8.

394 Liu MB, Xu SR, He Y, Deng GH, Sheng HF, Huang XM, Ouyang CY and Zhou HW (2013). Diverse vaginal
395 microbiomes in reproductive-age women with vulvovaginal candidiasis. *PLoS one* 8: e79812.

396 Liu X, Zha J, Chen H, Nishitani J, Camargo P, Cole SW and Zack JA (2003). Human immunodeficiency
397 virus type 1 infection and replication in normal human oral keratinocytes. *Journal of virology* 77:
398 3470-6.

399 Magerus-Chatinet A, Yu H, Garcia S, Ducloux E, Terris B and Bomsel M (2007). Galactosyl ceramide
400 expressed on dendritic cells can mediate HIV-1 transfer from monocyte derived dendritic cells to
401 autologous T cells. *Virology* 362: 67-74.

402 Maher D, Wu X, Schacker T, Horbul J and Southern P (2005). HIV binding, penetration, and primary
403 infection in human cervicovaginal tissue. *Proceedings of the National Academy of Sciences of the*
404 *United States of America* 102: 11504-9.

405 Malamud D and Wahl SM (2010). The mouth: a gateway or a trap for HIV? *AIDS* 24: 5-16.

406 Margolis L and Shattock R (2006). Selective transmission of CCR5-utilizing HIV-1: the 'gatekeeper'
407 problem resolved? *Nat Rev Microbiol* 4: 312-7.

408 Miller CJ and Shattock RJ (2003). Target cells in vaginal HIV transmission. *Microbes and infection /*
409 *Institut Pasteur* 5: 59-67.

410 Milman G and Sharma O (1994). Mechanisms of HIV/SIV mucosal transmission. *AIDS research and*
411 *human retroviruses* 10: 1305-12.

412 Milush JM, Kosub D, Marthas M, Schmidt K, Scott F, Wozniakowski A, Brown C, Westmoreland S and
 413 Sodora DL (2004). Rapid dissemination of SIV following oral inoculation. *AIDS* 18: 2371-80.

414 Mondor I, Ugolini S and Sattentau QJ (1998). Human immunodeficiency virus type 1 attachment to
 415 HeLa CD4 cells is CD4 independent and gp120 dependent and requires cell surface heparans. *Journal*
 416 *of virology* 72: 3623-34.

417 Moore JS, Hall SD and Jackson S (2002). Cell-associated HIV-1 infection of salivary gland epithelial cell
 418 lines. *Virology* 297: 89-97.

419 Moore JS, Rahemtulla F, Kent LW, Hall SD, Ikizler MR, Wright PF, Nguyen HH and Jackson S (2003).
 420 Oral epithelial cells are susceptible to cell-free and cell-associated HIV-1 infection in vitro. *Virology*
 421 313: 343-53.

422 Niess JH, Brand S, Gu X, Landsman L, Jung S, McCormick BA, Vyas JM, Boes M, Ploegh HL, Fox JG,
 423 Littman DR and Reinecker HC (2005). CX3CR1-mediated dendritic cell access to the intestinal lumen
 424 and bacterial clearance. *Science* 307: 254-8.

425 Pierson TC and Doms RW (2003). HIV-1 entry and its inhibition. *Curr Top Microbiol Immunol* 281: 1-
 426 27.

427 Politch JA, Marathe J and Anderson DJ (2014). Characteristics and quantities of HIV host cells in
 428 human genital tract secretions. *The Journal of infectious diseases* 210 Suppl 3: S609-15.

429 Quinones-Mateu ME, Lederman MM, Feng Z, Chakraborty B, Weber J, Rangel HR, Marotta ML, Mirza
 430 M, Jiang B, Kiser P, Medvik K, Sieg SF and Weinberg A (2003). Human epithelial beta-defensins 2 and
 431 3 inhibit HIV-1 replication. *AIDS* 17: F39-48.

432 Richman DD, Margolis DM, Delaney M, Greene WC, Hazuda D and Pomerantz RJ (2009). The
 433 challenge of finding a cure for HIV infection. *Science* 323: 1304-7.

434 Roderiquez G, Oravec T, Yanagishita M, Bou-Habib DC, Mostowski H and Norcross MA (1995).
 435 Mediation of human immunodeficiency virus type 1 binding by interaction of cell surface heparan
 436 sulfate proteoglycans with the V3 region of envelope gp120-gp41. *Journal of virology* 69: 2233-9.

437 Rodriguez-Inigo E, Jimenez E, Bartolome J, Ortiz-Movilla N, Bartolome Villar B, Jose Arrieta J,
 438 Manzarbeitia F and Carreno V (2005). Detection of human immunodeficiency virus type 1 RNA by in
 439 situ hybridization in oral mucosa epithelial cells from anti-HIV-1 positive patients. *J Med Virol* 77: 17-
 440 22.

441 Roskoski R, Jr. (2014). The ErbB/HER family of protein-tyrosine kinases and cancer. *Pharmacological*
 442 *research : the official journal of the Italian Pharmacological Society* 79: 34-74.

443 Rothenberg RB, Scarlett M, del Rio C, Reznik D and O'Daniels C (1998). Oral transmission of HIV. *AIDS*
 444 12: 2095-105.

445 Shen R, Richter HE and Smith PD (2011). Early HIV-1 target cells in human vaginal and ectocervical
 446 mucosa. *Am J Reprod Immunol* 65: 261-7.

447 Smith DK, Grohskopf LA, Black RJ, Auerbach JD, Veronese F, Struble KA, Cheever L, Johnson M,
 448 Paxton LA, Onorato IM and Greenberg AE (2005). Antiretroviral postexposure prophylaxis after
 449 sexual, injection-drug use, or other nonoccupational exposure to HIV in the United States:
 450 recommendations from the U.S. Department of Health and Human Services. *MMWR.*
 451 *Recommendations and reports : Morbidity and mortality weekly report. Recommendations and*
 452 *reports / Centers for Disease Control* 54: 1-20.

453 Spira AI, Marx PA, Patterson BK, Mahoney J, Koup RA, Wolinsky SM and Ho DD (1996). Cellular
 454 targets of infection and route of viral dissemination after an intravaginal inoculation of simian
 455 immunodeficiency virus into rhesus macaques. *J Exp Med* 183: 215-25.

456 Tugizov SM, Herrera R, Velupillai P, Greenspan D, Soros V, Greene WC, Levy JA and Palefsky JM
 457 (2011). HIV is inactivated after transepithelial migration via adult oral epithelial cells but not fetal
 458 epithelial cells. *Virology* 409: 211-22.

459 Tugizov SM, Herrera R, Velupillai P, Greenspan D, Soros V, Greene WC, Levy JA and Palefsky JM
 460 (2012). Differential transmission of HIV traversing fetal oral/intestinal epithelia and adult oral
 461 epithelia. *Journal of virology* 86: 2556-70.

462 UNAIDS (2015). How AIDS changed everything - Fact sheet 2014 statistics
 463 http://www.unaids.org/en/resources/documents/2015/20150714_factsheet.

464 Vacharaksa A, Asrani AC, Gebhard KH, Fasching CE, Giacaman RA, Janoff EN, Ross KF and Herzberg
 465 MC (2008). Oral keratinocytes support non-replicative infection and transfer of harbored HIV-1 to
 466 permissive cells. *Retrovirology* 5: 66.

467 van den Berg LM and Geijtenbeek TB (2013). Antiviral immune responses by human langerhans cells
 468 and dendritic cells in HIV-1 infection. *Adv Exp Med Biol* 762: 45-70.

469 van Kooyk Y and Geijtenbeek TB (2003). DC-SIGN: escape mechanism for pathogens. *Nat Rev*
 470 *Immunol* 3: 697-709.

471 Walsh LJ, Ishii T, Savage NW, Gemmell E and Seymour GJ (1990). Immunohistologic analysis of
 472 epithelial cell populations in oral lichen planus. *Journal of oral pathology & medicine : official*
 473 *publication of the International Association of Oral Pathologists and the American Academy of Oral*
 474 *Pathology* 19: 177-81.

475 Weinberg A, Naglik JR, Kohli A, Tugizov SM, Fidel PL, Jr., Liu Y and Herzberg M (2011). Innate
 476 immunity including epithelial and nonspecific host factors: workshop 1B. *Advances in dental research*
 477 23: 122-9.

478 Wilkinson J and Cunningham AL (2006). Mucosal transmission of HIV-1: first stop dendritic cells.
 479 *Current drug targets* 7: 1563-9.

480 Wu Z, Chen Z and Phillips DM (2003). Human genital epithelial cells capture cell-free human
 481 immunodeficiency virus type 1 and transmit the virus to CD4+ Cells: implications for mechanisms of
 482 sexual transmission. *The Journal of infectious diseases* 188: 1473-82.

483 Yeaman GR, White HD, Howell A, Prabhala R and Wira CR (1998). The mucosal immune system in the
484 human female reproductive tract: potential insights into the heterosexual transmission of HIV. *AIDS*
485 *research and human retroviruses* 14 Suppl 1: S57-62.

486

487